Cargando…

Exercise With a Novel Digital Device Increased Serum Anti-influenza Antibody Titers After Influenza Vaccination

It has been reported that some exercise could enhance the anti-viral antibody titers after vaccination including influenza and coronavirus disease 2019 vaccines. We developed SAT-008, a novel digital device, consists of physical activities and activities related to the autonomic nervous system. We a...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Jun-Pyo, Ayoub, Ghazal, Ham, Jarang, Huh, Youngmin, Choi, Seung Eun, Hwang, Yu-Kyoung, Noh, Ji Yun, Kim, Sae-Hoon, Song, Joon Young, Kim, Eu Suk, Chang, Yoon-Seok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Immunologists 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10166655/
https://www.ncbi.nlm.nih.gov/pubmed/37179746
http://dx.doi.org/10.4110/in.2023.23.e18
Descripción
Sumario:It has been reported that some exercise could enhance the anti-viral antibody titers after vaccination including influenza and coronavirus disease 2019 vaccines. We developed SAT-008, a novel digital device, consists of physical activities and activities related to the autonomic nervous system. We assessed the feasibility of SAT-008 to boost host immunity after an influenza vaccination by a randomized, open-label, and controlled study on adults administered influenza vaccines in the previous year. Among 32 participants, the SAT-008 showed a significant increase in the anti-influenza antibody titers assessed by hemagglutination-inhibition test against antigen subtype B Yamagata lineage after 4 wk of vaccination and subtype B Victoria lineage after 12 wk (p<0.05). There was no difference in the antibody titers against subtype “A.” The SAT-008 also showed significant increase in the plasma cytokine levels of IL-10, IL-1β, and IL-6 at weeks 4 and 12 after the vaccination (p<0.05). A new approach using the digital device may boost host immunity against virus via vaccine adjuvant-like effects. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04916145